Tasco Holdings International (OTCBB: THII) Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
Geoffrey Eiten, president of National Financial Communications, said, “With worldwide spending on medical research and technology growing at enormous rates — more than $14 billion in public and private funds is expected to be spent on stem cell research alone this year — agencies, such as those that offer stem cell research and related products, services and facilities stand to benefit over the near and long term. And their market positioning couldn’t be timelier to public funding debates.
“Having already invested substantial capital to construct and outfit a first-of-its-kind 15,000 square foot, FDA-compliant cGMP (Good Manufacturing Practices) and cGTP (Good Tissue Practices) facility for adult stem cell storage and research in the U.S., Tasco is uniquely positioned to capture its share of the estimated $75 billion a year biotech and medical device industry.”
Sources:
Beacon Equity Research – http://www.BeaconEquityResearch.com
Business Wire
Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517
About Tasco Holdings Inc.
Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.
The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.
Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.
�
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.
Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.